Have you ever wondered what really makes your employees tick when it comes to their health and wellbeing? What drives them to move, eat well, switch off mentally or what silently holds them back? Each November, millions join Movember to spark conversation and action around men’s physical and mental health. At Purdie Pascoe, we’ve taken part for the last few years. But this year, we wanted to go a step further. Instead of just looking outward, we turned the lens on ourselves.

As we all start to get into the festive spirit ahead of the holiday season, it’s a perfect time to reflect on achievements, and of course challenges across the past year. 2025 has been a big year for Purdie Pascoe, and in this short interview, Co-Founder Guy Pascoe provides insight into what has made this year so pivotal for the business.

SABCS is one of the world’s most influential scientific meetings dedicated to breast cancer research and treatment. Are you attending? Meet Parisa Valadan, Associate Director to discuss how our team can help you clarify your strategy and uncover opportunities to accelerate impact.

Our dedicated division has evolved. While PMCF remains a core part of our offering, we’re now applying our expertise to broader areas, including other forms of Real World Data (RWD) collection and Post Market Performance Follow-Up (PMPF). In this conversation, Marcus and Ellie discuss the why behind the expansion of our services, the evolution of the team, and what it means for our clients at Purdie Pascoe.

Beneath the white coats, doctors are still human. They respond to good stories, authentic visuals, and messages that feel credible and relevant.  At Purdie Pascoe, ad testing continues to be one of the most revealing parts of our work, helping medical device manufacturers understand not just what their audiences say they want, but what they actually respond to.

In this piece, Marcus Torr, Head of Post Market Surveys, shares his reflections on the discussions shaping the regulatory landscape, the themes emerging across both events, and how continued collaboration can drive meaningful improvements in patient safety and lifecycle management.

Imagine a simple blood test that could screen for dozens of cancers, long before symptoms appear. This is the promise of Multi-Cancer Early Detection (MCED), a rapidly emerging field that has the potential to transform how we approach cancer screening globally. As with any breakthrough, the success of MCED will depend not only on the science, but also on public awareness, understanding and interest, healthcare system readiness, and equitable access.

By analysing data through a more granular lens, including disaggregation by gender, we can uncover meaningful insights, identify differential responses, and ultimately drive more equitable outcomes for all patient groups. Doing so also supports alignment with regulatory expectations around inclusive and evidence based post-market surveillance.

Sabera Hyderally, Purdie Pascoe’s Head of US MedTech, recently facilitated an engaging, honest, and thought-provoking conversation with experts from across the MedTech and Diagnostics industry. The discussion explored how MedTech differs from other sectors, particularly pharmaceuticals, and what these differences mean for how we approach market research, innovation, and patient engagement. 

Attending this year’s RAPS Congress we were reminded of why we do what we do; at the heart of every conversation from regulatory reform to AI innovation there was one shared purpose: improving patients’ lives.

Are you attending the RAPS European Lifecycle Management Conference from 28-29 October? Purdie Pascoe’s Head of Post Market Surveys, Marcus Torr will be attending and presenting.

With over 50 of us now based across the UK, US, and Europe, this year’s meeting was a true celebration of our growth, our people, and our commitment to MedTech. Fittingly, our theme this year was bold and simple: MedTech, as it’s not just one of our sectors - it’s our sole focus.

While quantitative data can reveal what is happening, qualitative insights uncover the why; shedding light on patient experiences, clinician workflows, and unmet needs that numbers alone can't capture. By diving deep into real-world perspectives, MedTech companies can design more intuitive devices, craft compelling value propositions, and navigate complex regulatory and reimbursement landscapes with greater confidence.

Post-Market Clinical Follow-up (PMCF) surveys can help address clinical data gaps that may impact the ongoing assessment of a medical device’s safety and performance. Unearthing clinical gaps requires a systematic approach, including a review of clinical literature, post-market surveillance data, and regulatory compliance standards.

As we navigate through the busy conference season, the industry is buzzing with innovation, networking, and knowledge sharing. Conferences are pivotal events that drive advancements, offering a unique platform for professionals to stay ahead of the curve. However, the true value of these events lies in the insights they generate.

We are delighted to be attending MedDev Day from 13-14 October 2025 in Budapest. Purdie Pascoe’s Head of Post Market Surveys, Marcus Torr will be attending and presenting at the conference.

Our client, a market-leading provider of vascular surgery products for aortic and peripheral vascular disease, wanted to understand how they could better service interventional cardiologists (ICs) and their patients by understanding ICs’ preferences, perceptions, and influences and priorities.

We are delighted to be the exhibiting at the RAPS Convergence, 7-9 October 2025 in Pittsburgh, US. Purdie Pascoe’s Post Market Survey experts Ellie Baker, Commercial Director and Chris Webb Research Manager | RCC- MDR are exhibiting on Booth 817.

As the ctDNA cancer monitoring market becomes increasingly competitive, established panels continue to maintain their foothold amidst a surge of new entrants. Purdie Pascoe is conducting an ongoing syndicated study exploring the US ctDNA Cancer Monitoring Landscape. Waves 1 through 3 are available for immediate purchase, with Wave 4 launching soon.

Experts presenters from across the industry; Breda Kearny - Clinical Regulatory Lead, BSI, Diane M. Legere - Senior Clinical Auditor, DNV, Marcus Torr - Head of Post Market Surveys, Purdie Pascoe and Efsthathios Vassiliadis - CEO, Evnia.